Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript

2025-08-07 20:01:43 ET

Ligand Pharmaceuticals Incorporated (LGND)

Q2 2025 Earnings Conference Call

August 07, 2025 08:30 AM ET

Company Participants

Lauren Hay - Corporate Participant

Melanie Herman - Corporate Participant

Octavio Espinoza - Chief Financial Officer

Paul J. Hadden - Senior Vice President of Investments & Business Development

Todd C. Davis - CEO & Director

Conference Call Participants

Douglas Miehm - RBC Capital Markets, Research Division

John D. Vandermosten - Zacks Small-Cap Research

Lawrence Scott Solow - CJS Securities, Inc.

Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division

Trevor Thomas Allred - Oppenheimer & Co. Inc., Research Division

Presentation

Operator

Good day, and welcome to the Ligand Second Quarter 2025 Earnings Call. [Operator Instructions] And finally, I would like to advise all participants that this call is being recorded. Thank you.

I'd now like to welcome Melanie Herman, Executive Director of Investor Relations, to begin the conference. Melanie, over to you....

Read the full article on Seeking Alpha

For further details see: